Reported about 20 hours ago
Guggenheim has reaffirmed its Buy rating on Eli Lilly & Company (NYSE:LLY), setting a price target of $875. The firm cites strong demand for tirzepatide in treating diabetes and obesity, alongside the anticipated launch of orforglipron to bolster global growth. Eli Lilly's impressive financial performance, including an 82.64% gross profit margin and a 36.83% revenue increase year-over-year, further establishes its position in the pharmaceutical industry. Additionally, FDA approval for Guardant Health's diagnostic tool related to Eli Lilly’s breast cancer medication adds a significant boost to its market standing.
Source: YAHOO